Drugs / r-hLH
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01735422 | Dec 1999 → Jul 2001 | female infertility | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | r-hLH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01735422 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human luteinizing hormone (r-hLH, LHadi®)” NCT01735422 ↗ |
| Route | Subcutaneous | “subcutaneously at a dose of 825 or 2750 or 5500 or 11,000 or 22,000 IU” NCT01735422 ↗ |